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Abstract: Survival of extremely preterm infants has increased over recent years, but bronchopulmonary
dysplasia (BPD) remains a major cause of morbidity. In the USA, BPD is the most common chronic
respiratory disorder of infancy and affects the pulmonary and overall health of 10,000 preterm infants
annually. Preclinical and clinical studies suggest a crucial role for lung inflammation and host immune
response in the pathogenesis of BPD. Inflammation may result from, amongst others, chorioamnionitis,
postnatal infection, ventilation, and the administration of oxygen. Infants with BPD have worse long-
term outcomes than those without chronic lung disease. They are more than twice as likely to be
readmitted to hospital in their first year of life and, having survived their primary hospitalizations, they
are more likely to die than very preterm infants without chronic lung disease. Survivors with BPD have
an increased risk of neurodevelopmental impairment and their respiratory function remains compromised
well into adolescence. As the first generations of extremely low birth weight (ELBW) survivors have not
yet reached retirement age, there are currently no reliable data addressing the association between BPD
and pulmonary diseases of the elderly such as chronic obstructive pulmonary disease. Although BPD is
quite common in ELBW infants, there are infants who do not develop BPD, which supports the argument
that BPD is a preventable disease, emphasizing the need for high-quality safety and efficacy prevention
studies. However, according to an Institute of Medicine statement regarding pediatric drug studies, the
therapeutic area that has the fewest drugs indicated for neonates is BPD. As inflammation seems to
be a primary mediator of injury in the pathogenesis of BPD, anti-inflammatory agents such as steroids
have long been the focus of preventive research activities. However, systemic steroids, although reducing
BPD, have frequently been linked to adverse neurodevelopmental outcomes and these considerations may
have contributed to the recently reported widespread use of inhaled corticosteroids in neonatal units
in North America and Europe. Inhaled corticosteroids were prescribed to 25% of infants born at <29
weeks of gestation with birth weights <1,500 g in neonatal units of 35 children’s hospitals in the USA.
According to a survey across all neonatal units in Germany, 46% administered inhaled corticosteroids
to preterm infants either as prophylaxis or treatment for BPD [10]. Pediatricians and neonatologists
should ask themselves whether the off-label use of inhaled corticosteroids in preterm infants is justifiable
in view of the available evidence. The authors of the pertinent review from the Cochrane Collaboration,
including 7 studies and 492 infants, conclude that there is currently no evidence to support the routine
use of inhaled steroids for the prevention of BPD. Recently, the primary outcome results of the Neonatal
European Study of Inhaled Steroids (NEUROSIS), including 863 very preterm infants (gestational age 23-
27 weeks), have been presented at scientific conferences, but the full study report is not yet published. By
contrast, intratracheal instillation of budesonide using surfactant as a vehicle has not yet become part of
clinical practice. There are fewer studies addressing the risks and benefits of this mode of administration.
In a randomized blinded pilot study in 116 very low birth weight infants who had severe radiographic
respiratory distress syndrome and required mechanical ventilation shortly after birth, early intratracheal
instillation of budesonide using surfactant as a vehicle resulted in significantly lower mean airway pressure
on day 1 and day 3 and a significantly lower oxygen index and PCO2 during the first 3 days compared
with infants in the control group who had received surfactant without corticosteroids. More infants were
extubated in the treatment group than in the controls at 1 and 2 weeks and the combined outcome of
death or chronic lung disease was significantly lower in the treatment group than in the control group
(19 of 60 vs. 34 of 56). No clinically significant adverse effects were observed during the study and at the
time of the follow-up assessment at 2-3 years of age. In the future, intratracheal instillation of budesonide
using surfactant as a vehicle may play a role in the prevention of BPD in ELBW infants. However, before
this therapy can be introduced into routine clinical care, remaining open questions need to be answered
and appropriately powered studies need to be performed.
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BPD and pulmonary diseases of the elderly such as chronic 
obstructive pulmonary disease.
Although BPD is quite common in ELBW infants, there are 
infants who do not develop BPD, which supports the argu-
ment that BPD is a preventable disease, emphasizing the 
need for high-quality safety and efficacy prevention studies. 
However, according to an Institute of Medicine statement 
regarding pediatric drug studies, the therapeutic area that 
has the fewest drugs indicated for neonates is BPD  [8] . As 
inflammation seems to be a primary mediator of injury in the 
pathogenesis of BPD, anti-inflammatory agents such as ste-
roids have long been the focus of preventive research ac-
tivities. However, systemic steroids, although reducing BPD, 
have frequently been linked to adverse neurodevelopmen-
tal outcomes and these considerations may have contribut-
ed to the recently reported widespread use of inhaled corti-
costeroids in neonatal units in North America and Europe. 
Inhaled corticosteroids were prescribed to 25% of infants 
born at <29 weeks of gestation with birth weights <1,500 g 
in neonatal units of 35 children’s hospitals in the USA  [9] . Ac-
cording to a survey across all neonatal units in Germany, 46% 
administered inhaled corticosteroids to preterm infants ei-
ther as prophylaxis or treatment for BPD  [10] . Pediatricians 
and neonatologists should ask themselves whether the off-
label use of inhaled corticosteroids in preterm infants is jus-
tifiable in view of the available evidence. The authors of the 
pertinent review from the Cochrane Collaboration, includ-
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 Abstract 
 Survival of extremely preterm infants has increased over re-
cent years, but bronchopulmonary dysplasia (BPD) remains 
a major cause of morbidity. In the USA, BPD is the most com-
mon chronic respiratory disorder of infancy and affects the 
pulmonary and overall health of 10,000 preterm infants an-
nually  [1] . Preclinical and clinical studies suggest a crucial 
role for lung inflammation and host immune response in the 
pathogenesis of BPD  [2] . Inflammation may result from, 
amongst others, chorioamnionitis, postnatal infection, ven-
tilation, and the administration of oxygen  [2] . Infants with 
BPD have worse long-term outcomes than those without 
chronic lung disease. They are more than twice as likely to be 
readmitted to hospital in their first year of life and, having 
survived their primary hospitalizations, they are more likely 
to die than very preterm infants without chronic lung dis-
ease  [3, 4] . Survivors with BPD have an increased risk of neu-
rodevelopmental impairment  [5] and their respiratory func-
tion remains compromised well into adolescence  [6, 7] . As 
the first generations of extremely low birth weight (ELBW) 
survivors have not yet reached retirement age, there are cur-
rently no reliable data addressing the association between 
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ing 7 studies and 492 infants, conclude that there is current-
ly no evidence to support the routine use of inhaled steroids 
for the prevention of BPD  [11] . Recently, the primary out-
come results of the Neonatal European Study of Inhaled Ste-
roids (NEUROSIS), including 863 very preterm infants (gesta-
tional age 23–27 weeks), have been presented at scientific 
conferences, but the full study report is not yet published 
 [12] .
By contrast, intratracheal instillation of budesonide using 
surfactant as a vehicle has not yet become part of clinical 
practice. There are fewer studies addressing the risks and 
benefits of this mode of administration. In a randomized 
blinded pilot study in 116 very low birth weight infants who 
had severe radiographic respiratory distress syndrome and 
required mechanical ventilation shortly after birth, early in-
tratracheal instillation of budesonide using surfactant as a 
vehicle resulted in significantly lower mean airway pressure 
on day 1 and day 3 and a significantly lower oxygen index 
and PCO 2 during the first 3 days compared with infants in the 
control group who had received surfactant without cortico-
steroids  [13] . More infants were extubated in the treatment 
group than in the controls at 1 and 2 weeks and the com-
bined outcome of death or chronic lung disease was signifi-
cantly lower in the treatment group than in the control 
group (19 of 60 vs. 34 of 56). No clinically significant adverse 
effects were observed during the study and at the time of the 
follow-up assessment at 2–3 years of age  [14] . In the future, 
intratracheal instillation of budesonide using surfactant as a 
vehicle may play a role in the prevention of BPD in ELBW in-
fants. However, before this therapy can be introduced into 
routine clinical care, remaining open questions need to be 
answered and appropriately powered studies need to be 
performed.  © 2015 S. Karger AG, Basel 
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